Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives
{{output}}
Lung cancer is the leading killer of both men and women in the US, and the 5-year survival remains poor. However, the approval of checkpoint blockade immunotherapy has shifted the treatment paradigm and provides hope for improved survival. The ability of non-s... ...